Grant: Fellowship - Priority Announcement: Gastroenterology
University of Alberta
$45,000.00
Screening for Novel NS5B-Inhibitors: Toward Selective and Potent Hepatitis C Virus (HCV) Therapy.
FY 2012-13
Summary
Over 170 million people are living with persistent hepatitis C (HCV) infection in the world, with about 300,000 infected people in Canada alone. No vaccine or potent, well-tolerated drugs are available despite 23 years of research since the discovery of the virus and there is still no licensed drug that specifically targets the HCV polymerase. Current standard therapy often fails, has very substantial side effects and is very expensive. Our proposal aims at using new computer based methods to develop potent and more tolerable drugs to stop the replication of HCV. Our goal is to inhibit the activity of the viral enzyme that is responsible for HCV replication. The new methods we intend to use have been proven successful for other drug targets recently. Our proposal combines state-of-the-art computer based modeling approaches with cutting-edge experimental validation protocols. Computer-based methods will allow us to screen in silico a large number of small molecules (~1,000,000) based on their ability to bind and stop the activity of this enzyme. We expect to find approximately 100 molecules (hits) by this computer-based method and then these molecules will be subjected to experimental validation. The proposed experimental validation is very specific and is three stages. During the first stage, all small molecules will be tested for their ability to stop HCV replication and for their toxicity to cells. During the second stage, further analysis of toxicity factors related to possible side effects (e.g. myopathy and severe anemia) will be performed. Finally, efficacy of the promising molecules will be tested using a humanized mouse model in which human liver is infected with HCV. Active compounds will then be modified using the initial computational approach, serving as seeds for an optimized collection of small molecules with improved binding abilities to the enzyme. The ultimate goal of our proposal is to develop a rationally designed new class of HCV drugs.
Department
Program
Fellowship - Priority Announcement: Gastroenterology
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
270559
Name
Barakat Khaled H
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Aptalis (Mont-Saint-Hilaire, Quebec); Canadian Association of Gastroenterology (Oakville, Ontario)
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Screening for Novel NS5B-Inhibitors: Toward Selective and Potent Hepatitis C Virus (HCV) Therapy.
Programtype2
Fellowship Programs
Orgnameinp2
University of Alberta
Cihramount2
$45,000
Cihrequipment2
$0
Programname2
Fellowship - Priority Announcement: Gastroenterology
Keyworddelim
Virology; Virtual Screening
Abstract
Over 170 million people are living with persistent hepatitis C (HCV) infection in the world, with about 300,000 infected people in Canada alone. No vaccine or potent, well-tolerated drugs are available despite 23 years of research since the discovery of the virus and there is still no licensed drug that specifically targets the HCV polymerase. Current standard therapy often fails, has very substantial side effects and is very expensive. Our proposal aims at using new computer based methods to develop potent and more tolerable drugs to stop the replication of HCV. Our goal is to inhibit the activity of the viral enzyme that is responsible for HCV replication. The new methods we intend to use have been proven successful for other drug targets recently. Our proposal combines state-of-the-art computer based modeling approaches with cutting-edge experimental validation protocols. Computer-based methods will allow us to screen in silico a large number of small molecules (~1,000,000) based on their ability to bind and stop the activity of this enzyme. We expect to find approximately 100 molecules (hits) by this computer-based method and then these molecules will be subjected to experimental validation. The proposed experimental validation is very specific and is three stages. During the first stage, all small molecules will be tested for their ability to stop HCV replication and for their toxicity to cells. During the second stage, further analysis of toxicity factors related to possible side effects (e.g. myopathy and severe anemia) will be performed. Finally, efficacy of the promising molecules will be tested using a humanized mouse model in which human liver is infected with HCV. Active compounds will then be modified using the initial computational approach, serving as seeds for an optimized collection of small molecules with improved binding abilities to the enzyme. The ultimate goal of our proposal is to develop a rationally designed new class of HCV drugs.
Competitiondate
201210
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Barakat, Khaled H
Approvedterm
2 ans 0 mois
Cihrcontribution2
Patient Oriented Research~ $45,000~ $0~